Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...

The Biden administration on Friday released the next round of prescription drugs selected for Medicare price negotiations, ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start ...

Also in today’s edition: ‘no-show’ international student data and significant progress in Israel-Hamas ceasefire talks ...

Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...

(Reuters) -Weight-loss drug developer Metsera, backed by ARCH Venture Partners, revealed a wider loss in its paperwork for a ...

Canadian public and private insurers have balked at covering certain medication for weight-loss, but that might change as the ...

The latest glucagon-like peptide 1 (GLP-1) receptor agonists have been heralded for their potential to not only boost weight loss and glucose ... tirzepatide, and new GLP-1 drugs in the research ...

Weight loss drugs catapulted many into a new wellness era, and gave hope to those with diabetes, obesity and who struggled to lose weight. The global anti-obesity drugs market — including the ...